New diabetes drug safety check underway in pakistan
NCT ID NCT05164263
First seen Jan 31, 2026 · Last updated Jun 19, 2026 · Updated 12 times
Summary
This study is checking how safe and well-tolerated the diabetes drug empagliflozin (taken with or without metformin) is in Pakistani adults with type 2 diabetes. About 2000 people aged 18-65 with poorly controlled blood sugar will be followed for 6 months. The study will track side effects like low blood sugar, infections, and dehydration, and also measure how well the drug controls blood sugar and weight.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SAFETY ISSUES are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Agha Khan univeristy hospital
RECRUITINGNairobi, Kenya, Kenya
Contact
-
Kabul University of Medical Sciences(KUMS)
COMPLETEDKabul, Afghanistan, Afghanistan
-
Lagos University Teaching Hospital
RECRUITINGLagos, Nigeria, Nigeria
Contact
Contact
Contact
-
NHK
COMPLETEDKandy, Kandy, Sri Lanka
-
National hospital Sri Lanka
COMPLETEDColombo, Colombo, Sri Lanka
-
Umar Diabetes Foundation
COMPLETEDIslamabad, Pakistan
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.